Clinical significance of basal-like subtype in triple-negative breast cancer

Breast Cancer

Volumn 16, Issue 4, 2009, Pages 260-267

  Yamamoto, Yutaka ^a   Ibusuki, Mutsuko ^a   Nakano, Masahiro ^a   Kawasoe, Teru ^a   Hiki, Ryousuke ^b   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Department of Surgery   (Japan)

Author keywords

Basal like subtype; CK5 6; EGFR; Triple negative breast cancer

Indexed keywords

AURORA A KINASE; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; STEM CELL FACTOR;

ADULT; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; KERATINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 70349673103     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0150-8     Document Type: Conference Paper

References (36)

1. L Harris H Fritsche R Mennel L Norton P Ravdin S Taube, et al. 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 17954709 10.1200/JCO.2007.14.2364 1:CAS:528:DC%2BD2sXhsVKnsbzK (Pubitemid 350232263)
2. G Konecny G Pauletti M Pegram M Untch S Dandekar Z Aguila, et al. 2003 Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 142 153 12529347 1:CAS:528:DC%2BD3sXovFelug%3D%3D (Pubitemid 36193263)
3. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 2470152 10.1126/science.2470152 1:STN:280: DyaL1M3kt1Wntg%3D%3D
4. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio, et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 17438091 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D (Pubitemid 46698581)
5. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 17671126 10.1158/1078-0432.CCR-06-3045 (Pubitemid 47219710)
6. BG Haffty Q Yang M Reiss T Kearney SA Higgins J Weidhaas, et al. 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652 5657 17116942 10.1200/JCO.2006.06.5664 (Pubitemid 46631305)
7. EA Rakha ME El-Sayed AR Green AH Lee JF Robertson IO Ellis 2007 Prognostic markers in triple-negative breast cancer Cancer 109 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D (Pubitemid 46120191)
8. M Tischkowitz JS Brunet LR Begin DG Huntsman MC Cheang LA Akslen, et al. 2007 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 134 17650314 10.1186/1471-2407-7-134 (Pubitemid 47272190)
9. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 1721 1728 17387718 10.1002/cncr.22618 (Pubitemid 46668532)
10. LN Harris G Broadwater NU Lin A Miron SJ Schnitt D Cowan, et al. 2006 Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 Breast Cancer Res 8 R66 17129383 10.1186/bcr1622 (Pubitemid 350201714)
11. GJ Morris S Naidu AK Topham F Guiles Y Xu P McCue, et al. 2007 Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database Cancer 110 876 884 17620276 10.1002/cncr.22836 (Pubitemid 47257667)
12. S Cleator W Heller RC Coombes 2007 Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235 244 17329194 10.1016/S1470-2045(07)70074- 8 (Pubitemid 46291713)
13. JS Reis-Filho AN Tutt 2008 Triple negative tumours: a critical review Histopathology 52 108 118 18171422 10.1111/j.1365-2559.2008.03046.x 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D (Pubitemid 351724916)
14. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
15. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 12829800 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
16. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
17. M van de Rijn CM Perou R Tibshirani P Haas O Kallioniemi J Kononen, et al. 2002 Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 161 1991 1996 12466114
18. I Matos R Dufloth M Alvarenga LC Zeferino F Schmitt 2005 p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas Virchows Arch 447 688 694 16012853 10.1007/s00428-005-0010-7 1:CAS:528:DC%2BD2MXhtFKqt7zM (Pubitemid 41571183)
19. S Kobayashi 2008 Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance Breast Cancer 15 153 158 18311481 10.1007/s12282-008-0034-3
20. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 16115903 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
21. FC Bidard R Conforti T Boulet S Michiels S Delaloge 2007 Andre F.egative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers Ann Oncol 18 1285 1286 17675400 10.1093/annonc/mdm360 (Pubitemid 47244379)
22. DS Tan C Marchio RL Jones K Savage IE Smith M Dowsett, et al. 2008 Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res Treat 111 27 44 17922188 10.1007/s10549-007-9756-8 1:CAS:528:DC%2BD1cXos1Wnsbs%3D (Pubitemid 352009225)
23. MC Cheang D Voduc C Bajdik S Leung S McKinney SK Chia, et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368 1376 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D
24. M Sasa Y Bando M Takahashi T Hirose T Nagao 2008 Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer J Surg Oncol 97 30 34 17929254 10.1002/jso.20906
25. Y Yamamoto M Ibusuki Y Okumura T Kawasoe K Kai K Iyama, et al. 2008 Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer Breast Cancer Res Treat 110 465 475 17805961 10.1007/s10549-007- 9742-1 1:CAS:528:DC%2BD1cXosVOgt7s%3D (Pubitemid 351962589)
26. R Bos P van der Groep AE Greijer A Shavarts S Meijer HM Pinedo, et al. 2003 Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma Cancer 97 1573 1581 12627523 10.1002/cncr.11246 (Pubitemid 36297788)
27. ME Royce W Xia AA Sahin H Katayama DA Johnston G Hortobagi, et al. 2003 STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis Cancer 100 12 19 10.1002/cncr.11879
28. A Goldhirsch WC Wood RD Gelber AS Coates B Thurlimann HJ Senn 2003 Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 3357 3365 12847142 10.1200/JCO.2003.04.576 (Pubitemid 46606270)
29. F Spyratos M Ferrero-Pous M Trassard K Hacene E Phillips M Tubiana-Hulin, et al. 2002 Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value Cancer 94 2151 2159 12001111 10.1002/cncr.10458 1:CAS:528:DC%2BD38Xjs12gtL8%3D (Pubitemid 34411971)
30. S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 9438854 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D (Pubitemid 28067289)
31. PG Natali MR Nicotra I Sures M Mottolese C Botti A Ullrich 1992 Breast cancer is associated with loss of the c-kit oncogene product Int J Cancer 52 713 717 1385336 10.1002/ijc.2910520508 1:STN:280:DyaK3s%2Flt1ymtA%3D%3D
32. X Chui H Egami J Yamashita T Kurizaki H Ohmachi S Yamamoto, et al. 1996 Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues Br J Cancer 73 1233 1236 8630284 1:STN:280:DyaK283it1CmsA%3D%3D
33. O Gautschi J Heighway PC Mack PR Purnell PN Lara DR Gandara Jr 2008 Aurora kinases as anticancer drug targets Clin Cancer Res 14 1639 1648 18347165 10.1158/1078-0432.CCR-07-2179 1:CAS:528:DC%2BD1cXjtlejtrY%3D
34. JR Bischoff L Anderson Y Zhu K Mossie L Ng B Souza, et al. 1998 A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers EMBO J 17 3052 3065 9606188 10.1093/emboj/17.11.3052 1:CAS:528:DyaK1cXjvFeisro%3D (Pubitemid 28254378)
35. H Zhou J Kuang L Zhong WL Kuo JW Gray A Sahin, et al. 1998 Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation Nat Genet 20 189 193 9771714 10.1038/2496 1:CAS:528: DyaK1cXms1eis78%3D (Pubitemid 28455454)
36. Y Nadler RL Camp C Schwartz DL Rimm HM Kluger Y Kluger 2008 Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer Clin Cancer Res 14 4455 4462 18628459 10.1158/1078-0432.CCR-07-5268 1:CAS:528:DC%2BD1cXosFGit7k%3D